BJDX
Bluejay Diagnostics, Inc. · Healthcare
Insiders bought $222K of Bluejay Diagnostics, Inc. in the last 12 months
6 insiders bought on 2 days.
BJDX over the last year
Largest buyers, last 12 months
BJDX after insider buys
3 months after each buy, from the first price a copier could get.
3 buys since 2022 with 3 months of prices.
Every filing
8 insider filings since 2022, newest first
HRT FINANCIAL LP · 10% owner
Douglas Clark Wurth · Director
Indranil Dey · President and CEO
Donald R Chase · Director
Fred S Zeidman · Director
Svetlana Dey · Director
Douglas Clark Wurth · Director and 10% owner
Douglas Clark Wurth · Director and 10% owner
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.